Ovid Therapeutics Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$718K
R&D↑+11.2% +$666K
$7M
SG&A
—
D&A↓-89.4% -$143K
$17K
Operating Income↑+5.3% +$703K
$-13M
EBITDA↓-89.4% -$143K
$17K
Interest Income↑+30.3% +$197K
$847K
Other Income/Expense↑+103.6% +$2M
$62K
Pretax Income↑+13.2% +$2M
$-12M
Tax Provision
$0
Net Income↑+13.2% +$2M
$-12M
Operating Margin↓-1842.0pts
-9487.1%
Net Margin↓-1114.7pts
-9210.6%
Effective Tax Rate↑+0.0pts
0.0%
ETR (Continuing Operations)↓-0.5pts
-0.5%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.0pts
0.0%
ETR Foreign Differential (pp)
0.3%
Operating Lease Cost↑+0.0% +$0
$542K
Revenue YoY Variation↓-82.4pts
-23.7%
Income YoY Variation↑+15.3pts
5.3%
Revenue QoQ Variation
443.9%
Income QoQ Variation↓-182.4pts
-146.9%